Investors |

News

03 January 2019

LexaGene was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018.

Read More

10 December 2018

LexaGene announces completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority of all clinical canine UTI cases.

Read More

03 December 2018

LexaGene recently had an Industry Engagement Meeting with the Department of Homeland Security (DHS) regarding the applications of the company’s technology for DHS’ program on Countering Weapons of Mass Destruction (CWMD).

Read More

28 November 2018

LexaGene named one of the 10 Most Promising Food and Beverages Solution Providers in 2018 by CIOReview.

Read More

22 October 2018

LexaGene successfully unveils LX2™ beta prototype design on October 20th, 2018 to an enthusiastic gathering of veterinary professionals at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference.

Read More

09 October 2018

LexaGene to unveil LX2™ Beta Prototype design for the veterinary market at an upcoming industry event.

Read More

04 September 2018

LexaGene announces that company President, Daryl Rebeck, will present at two upcoming investor conferences that are taking place in September 2018

Read More

26 July 2018

LexaGene announces that the company has begun beta development of its flagship pathogen detection system.

Read More

11 July 2018

LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.

Read More

19 June 2018

LexaGene announces C$5.0 Million bought deal with a syndicate of underwriters led by Canaccord Genuity Corp.

Read More

18 June 2018

LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.

Read More

06 June 2018

LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene’s LX6 prototype.

Read More